Company profile
Kalaris Therapeutics Inc
NASDAQ: KLRS · Healthcare · Biotechnology
#1017 of 1,418 Healthcare companies by revenue
EA Score
30DFH 34DQ 20GM —SS 43
v0.1 · 55/100 weight · provisional
↑ balance-sheet leverage, market scale · ↓ disclosure history, Piotroski F
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$43.4M
Employees
20
as of 2026-08-18
Market cap
$86.7M
as of 2026-08-18
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$165.0k$165.0k2020
Net income-$43.4M-$43.4M2025
Operating income-$46.2M-$46.2M2025
Total assets$121.7M$121.7M2025
Liabilities$42.9M$42.9M2025
Equity$78.8M$78.8M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Kalaris Therapeutics Inc’s revenue?
Kalaris Therapeutics Inc booked $165.0k in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -26326.1% net margin.
Peers · Healthcare
Eden Empire Inc.——Lisata Therapeutics, Inc.39DInnerScope Hearing Technologies, Inc.——Curative Biosciences, Inc.——ZIVO Bioscience, Inc.——Cannabis Strategic Ventures——Neighbors
Middlesex →Key facts
CEOAndrew Oxtoby
SectorHealthcare
IndustryBiotechnology
HeadquartersCambridge, MA
ExchangeNASDAQ: KLRS
Employees20
IPO date2020-07-30
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.